Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Operations: The Company is a Nevada holding company with operations conducted in the People's Republic of China (PRC) through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. It develops, manufactures, and markets pharmaceutical products, including injectables, tablets, and capsules. The Company is classified as a "smaller reporting company" and a "non-accelerated filer."
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $1,931,876 | $2,162,054 |
| Gross Profit | $369,053 | $(223,071) |
| Gross Margin | 19.1% | (10.3%) |
| Net Loss | $(2,601,271) | $(1,313,939) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.40) |
| Cash and Cash Equivalents (End of Period) | $304,874 | $625,032 |
| Total Assets | $44,709,903 | $30,999,464 |
| Total Liabilities | $8,528,623 | $8,259,712 |
| Stockholders' Equity | $36,181,280 | $22,739,752 |
Liquidity & Debt: As of June 30, 2026, current liabilities ($7.68 million) exceeded current assets ($2.01 million) by approximately $5.7 million. The Company holds borrowings from related parties of $1.64 million and lines of credit of $1.96 million. Cash flow from operating activities was negative $88,120 for the six-month period.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 10.6% year-over-year to $1.93 million. This was driven by a 42% drop in the "Anti-Viral/Infection & Respiratory" category due to market fluctuations and centralized procurement policies, partially offset by a 34% increase in "CNS Cerebral & Cardio Vascular" products.
- Profitability Shift: The Company moved from a gross loss of $223,071 in the prior year to a gross profit of $369,053. This improvement was primarily due to machinery and equipment reaching the end of their useful lives, reducing depreciation costs.
- Increased Operating Expenses: General and administrative expenses surged to $2.60 million (from $0.95 million) due to the amortization of five new patented technologies acquired since August 2025. This drove the operating loss to $2.55 million, compared to $1.41 million in the prior period.
- Balance Sheet Expansion: Total assets increased significantly to $44.7 million, largely due to a $14.99 million issuance of common stock to acquire intangible assets (patents) in February 2026.
Outlook, Risks, and Unusual Items
- Going Concern: The Company has an accumulated deficit of $49.8 million and relies on advances from its Chairperson/CEO (Ms. Zhilin Li) and subsequent equity financing to maintain liquidity. Financial statements are prepared on a going concern basis.
- Subsequent Financing: On July 22, 2026, the Company entered into a securities purchase agreement to sell 2,500,000 shares at $2.00 per share, receiving net proceeds of $4.425 million to supplement operating cash flow.
- Regulatory & Market Risks: Operations are heavily dependent on PRC regulations, including the National Medical Products Administration (NMPA) consistency evaluations and Centralized Procurement (CP) programs, which have reduced prices for bid-winning drugs. The Company is also subject to foreign currency exchange risks as all revenue is denominated in Renminbi (RMB).
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness regarding a lack of accounting personnel knowledgeable in U.S. GAAP.
- Concentration Risk: For the six months ended June 30, 2026, two customers accounted for 26.9% of sales, and three suppliers accounted for 59.2% of raw material purchases.
Investor Verification Checklist
- Equity Dilution: Verify the impact of the 25 million shares issued for intangible assets and the subsequent 2.5 million shares sold in July 2026 on future earnings per share.
- Amortization Impact: Confirm the useful life assumptions for the newly acquired patents ($14.99 million value) and the resulting long-term impact on operating expenses.
- Liquidity Runway: Assess whether the $4.4 million in recent proceeds and existing related-party loans are sufficient to cover the current operating cash burn rate.
- Internal Control Remediation: Review the Company's plan to address the material weakness in internal controls over financial reporting.
- Product Pipeline: Monitor the status of consistency evaluations for key products to determine eligibility for future Centralized Procurement programs.